Answers are grounded in this paper and cite their sources.
Background/Objectives: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a standard therapy for hormone receptor-positive (HR + ), HER2-negative breast cancer and are frequently administered as long-term therapy. While their efficacy is comparable, differences in symptom burden, need for supportive interventions, and interaction liability may substantially influence patient experience, adherence, and quality of life in real-world practice. Evidence based on patient-reported outcomes (PROs) addressing supportive care needs remains limited. Methods: A cross-sectional, questionnaire-based observational study was conducted among 155 women with HR+ breast cancer treated with abemaciclib, ribociclib, or palbociclib plus endocrine therapy, or endocrine therapy alone (control). Patient-reported symptoms, perceived deterioration, and responses indicating additional medication use were analyzed. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for individual symptom outcomes using Fisher’s exact test with Benjamini–Hochberg correction for multiple comparisons. Exploratory pooled questionnaire-response outcomes were evaluated using patient-clustered logistic generalized estimating equations (GEE), without adjustment for potential confounders. BMI-stratified pooled-response analyses were considered exploratory. Results: Distinct patterns of patient-reported symptoms were observed across treatment groups. Abemaciclib was associated with higher odds of diarrhea and burdensome abdominal pain, whereas ribociclib was associated with higher odds of burdensome stomatitis/mucositis. Both agents were associated with increased reporting of burdensome nausea/vomiting. In exploratory GEE analyses, affirmative symptom responses were less frequent with ribociclib (OR 0.586, 95% CI 0.381–0.900; q = 0.022) and palbociclib (OR 0.353, 95% CI 0.230–0.541; q < 0.001), but not significantly different with abemaciclib (q = 0.073), compared with endocrine therapy alone. Responses indicating additional medication use were more frequent with abemaciclib (OR 2.192, 95% CI 1.380–3.484; q = 0.003), but not significantly different with ribociclib or palbociclib. BMI subgroup findings were exploratory and showed differences in symptom reporting during abemaciclib therapy. Conclusion: CDK4/6 inhibitors were associated with distinct patterns of patient-reported symptoms and supportive care needs. These findings highlight the importance of individualized symptom monitoring, structured medication review, and multidisciplinary supportive care during long-term breast cancer treatment.
No takes yet. Share an insight, caveat, or question.
Regulska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: